Hans Adomat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hans Adomat has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Alireza M. Rezakhanlou
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
40 shared publications - Beibei Zhai
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
40 shared publications - Colin Collins
Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
40 shared publications - Dennis Brown
Rakovina Therapeutics, Vancouver, British Columbia, Canada
40 shared publications - Fariba Ghaidi
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
40 shared publications - Htoo Zarni Oo
Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
40 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in Matrix Biology
- Vol. 149
Degradomic and transcriptomic profiling reveal pleiotropic roles of extracellular granzyme B in scarring and fibrosis
- 23 September 2026
- Published by Elsevier in Matrix Biology
- Vol. 149
Open AccessDegradomic and transcriptomic profiling reveal pleiotropic roles of extracellular granzyme B in scarring and fibrosis
- Open Access
- 4 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (49)
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer
HOXB13 is a lineage-specific transcription factor that plays a critical role in initiation and progression of prostate cancer (PCa). While most research has focused on the role of HOXB13 on androgen receptor (AR) activity, here we demonstrate that HOXB13 is frequently expressed in AR-negative tumors and is essential for the proliferation of both AR-positive and -negative PCa models. Strikingly, HOXB13 is remarkably selective and has almost no effect on nonprostatic tissues. Despite this common essentiality in PCa, HOXB13 activity is markedly different in AR-negative stem cell–like tumors, where interactions with the AP-1 change the HOXB13 cistrome and interactome. Yet despite these distinct activities, HOXB13 activity is commonly mediated by SMARCD2, a member of the mSWI/SNF chromatin remodeling complex. The HOXB13/SMARCD2 interaction alters chromatin accessibility at HOXB13-binding sites, causing increased proliferation in AR-negative PCa. Overall, this work demonstrates a distinct mechanism of action for HOXB13 and highlights its critical role in AR-negative castration-resistant PCa.
- 4 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (49)
Open AccessDistinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer
HOXB13 is a lineage-specific transcription factor that plays a critical role in initiation and progression of prostate cancer (PCa). While most research has focused on the role of HOXB13 on androgen receptor (AR) activity, here we demonstrate that HOXB13 is frequently expressed in AR-negative tumors and is essential for the proliferation of both AR-positive and -negative PCa models. Strikingly, HOXB13 is remarkably selective and has almost no effect on nonprostatic tissues. Despite this common essentiality in PCa, HOXB13 activity is markedly different in AR-negative stem cell–like tumors, where interactions with the AP-1 change the HOXB13 cistrome and interactome. Yet despite these distinct activities, HOXB13 activity is commonly mediated by SMARCD2, a member of the mSWI/SNF chromatin remodeling complex. The HOXB13/SMARCD2 interaction alters chromatin accessibility at HOXB13-binding sites, causing increased proliferation in AR-negative PCa. Overall, this work demonstrates a distinct mechanism of action for HOXB13 and highlights its critical role in AR-negative castration-resistant PCa.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicates of cell cycle assays and statistics
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicates of cell cycle assays and statistics
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Materials and methods for in vivo toxicity and cellular fluorescence assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Materials and methods for in vivo toxicity and cellular fluorescence assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of spheroid assays and cell fluorescence data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of spheroid assays and cell fluorescence data
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate data of DNA damage assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate data of DNA damage assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of HDAC, PARP1, PARP2 and PARylation assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of HDAC, PARP1, PARP2 and PARylation assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Blood cell panel counts and weight loss percentage of in vivo toxicity study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Blood cell panel counts and weight loss percentage of in vivo toxicity study
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate data of DNA damage assays
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate data of DNA damage assays